Cesca Therapeutics (KOOL) and Its Competitors Head to Head Review
Cesca Therapeutics (NASDAQ: KOOL) is one of 45 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Cesca Therapeutics to similar businesses based on the strength of its risk, earnings, dividends, analyst recommendations, valuation, profitability and institutional ownership.
This is a breakdown of recent ratings and recommmendations for Cesca Therapeutics and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cesca Therapeutics Competitors||194||914||1695||67||2.57|
As a group, “Biopharmaceuticals” companies have a potential upside of 6.99%. Given Cesca Therapeutics’ competitors stronger consensus rating and higher possible upside, analysts clearly believe Cesca Therapeutics has less favorable growth aspects than its competitors.
Insider and Institutional Ownership
2.5% of Cesca Therapeutics shares are owned by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 3.9% of Cesca Therapeutics shares are owned by company insiders. Comparatively, 14.9% of shares of all “Biopharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares Cesca Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cesca Therapeutics Competitors||-13,404.97%||246.04%||-20.09%|
Volatility and Risk
Cesca Therapeutics has a beta of -0.68, meaning that its share price is 168% less volatile than the S&P 500. Comparatively, Cesca Therapeutics’ competitors have a beta of 1.28, meaning that their average share price is 28% more volatile than the S&P 500.
Earnings & Valuation
This table compares Cesca Therapeutics and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Cesca Therapeutics||$14.52 million||-$6.21 million||-0.84|
|Cesca Therapeutics Competitors||$579.33 million||$241.73 million||-6.67|
Cesca Therapeutics’ competitors have higher revenue and earnings than Cesca Therapeutics. Cesca Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Cesca Therapeutics competitors beat Cesca Therapeutics on 10 of the 12 factors compared.
About Cesca Therapeutics
Cesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Company focuses on the business of research, development and commercialization of autologous cell-based therapeutics for use in the regenerative medicine industry. The Company’s therapeutic development initiatives focuses on the fields of cardiovascular medicine and orthopedic regeneration. The Company offers a range of products, such as SurgWerks System, CellWerks System, AutoXpress System (AXP), MarrowXpress System (MXP), BioArchive System, and manual bag sets for use in the processing and cryogenic storage of cord blood.
Receive News & Stock Ratings for Cesca Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics Inc. and related stocks with our FREE daily email newsletter.